Skip to main content Skip to section navigation Skip to footer

Home
Our story
Our focus
Our portfolio
For investors
- Company
- Stock
- SEC filings
- Governance
- Analysts
- News
- Events
Contact us
Sign up for email alerts

For investors

Company
Stock
SEC filings
Governance
Analysts
News
Events

Relmada Therapeutics, Inc.

Events

Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

Jul 27, 2021 8:30 AM EDT

Sign up for alerts

Our story
Our focus
Our portfolio
For investors
- Company
- Stock
- SEC filings
- Governance
- Analysts
- News
- Events
Contact us

©2024 Relmada Therapeutics, Inc. | Privacy Policy Terms of Use